Royalty Pharma plc Class A Ordinary Shares (RPRX) Analyst Ratings & Price Targets

Royalty Pharma plc Class A Ordinary Shares

RPRX · Nasdaq

Analyst Consensus

Buy

7 analysts

$68

Current

—

Low

$66

Average

—

High

Average target implies -2.63% versus the current price.

Analyst Ratings Synthesis

Consensus is Buy across seven analysts. The only target statistic supplied is a $66 mean; low and high targets are unavailable, so neither the target range nor a meaningful cluster can be described. The evidence names no analyst or brokerage at either end of the range and does not identify the most or least bullish view. It also contains no rating or target revisions during the past week, so revision direction cannot be established. The provided material therefore shows positive rating consensus but not the underlying debate: no analyst rationales or disagreements on royalty growth, portfolio concentration, policy exposure or valuation are reported.

Rating Actions

No individual rating actions have been captured for RPRX yet. Consensus figures above come from Nasdaq's aggregate feed.

Rating actions are extracted from published reporting. Each row links to its source.

Research Reports

Links to freely available third-party research. Outlook labels are our classification of each article's stance, not a rating of our own.

Covering Firms

B OF A GLBL RES

GOLDMAN SACHS

JP MORGAN SECUR

MORGAN STANLEY

TD COWEN

TIGRESS FINANCI

UBS

Symbol: RPRX
Type: Stock
Sector: Health Care
Industry: Biotechnology: Pharmaceutical Preparations
Country: North America
Exchange: Nasdaq

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry's leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators.

Key Issues

Bullish view

Royalty Pharma executives say the company is monitoring changes in the biopharma policy environment, while its royalty-focused model avoids some of the direct risks of developing drugs itself.

Bearish view

Policy changes could affect the economics of medicines generating royalties, and the supplied evidence does not identify the company's exposure or quantify potential effects.

Analyst Consensus

See all

Buy

7 analysts

$68

Current

—

Low

$66

Average

—

High

Average target implies -2.63% versus the current price.

Earnings History

BeatMissNo estimate

Royalty Pharma plc Class A Ordinary Shares

Analyst Consensus

Analyst Ratings Synthesis

Rating Actions

Research Reports

Covering Firms

Peers